Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27083571 | 0.84 | DAO (0.33) | IDO1TDO2 | |
| SCHEMBL23528853 | 0.84 | DAO (0.33) | IDO1TDO2 | |
| SCHEMBL17196435 | 0.81 | CHRNB4 (0.34) | CHRNB4CHRNA3 | |
| SCHEMBL12263051 | 0.78 | GABRA1 (0.38) | CHRNB4CHRNA3IDO1TDO2 | |
| SCHEMBL4059893 | 0.78 | CHRNB4 (0.39) | CHRNB4CHRNA3IDO1TDO2 | |
| SCHEMBL3592509 | 0.76 | CHRNB4 (0.34) | CHRNB4CHRNA3 | |
| SCHEMBL29988864 | 0.76 | CHRNB4 (0.34) | CHRNB4CHRNA3 | |
| SCHEMBL1006029 | 0.75 | GBA1 (0.36) | CHRNB4CHRNA3IDO1TDO2 | |
| SCHEMBL20764748 | 0.75 | CES2 (0.35) | CHRNB4CHRNA3CES2CES1 | |
| SCHEMBL28989624 | 0.75 | GABRA1 (0.35) | CHRNB4CHRNA3CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164835-A2 | PROCESS FOR PREPARING TRIAZOLONES | F. Hoffmann-Roche AG (CH) | 2010-03-24 | — | — | EP | claimed |
| CN-101679320-A | Process for preparing triazolones | HOFFMANN LA ROCHE | 2010-03-24 | — | — | CN | claimed |
| US-20090012304-A1 | preparation of intermediates 3-[3-(4-methyl-5-methylsulfanyl-4H-[1,2,4]triazol-3-ylmethyl)phenoxy]-5-difluoromethyl-benzonitrile derivatives; for making enzyme inhibitors of HIV-1 reverse transcriptase, treating AIDS and HIV-1 syndromes | ROCHE PALO ALTO LLC | 2009-01-08 | — | — | US | claimed |
| WO-2008145563-A2 | PROCESS FOR PREPARING TRIAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-04 | — | — | WO | claimed |
| US-12552826-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4635944-A1 | 2-AZABICYCLO[3.1.1]HEPTANE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2025-10-22 | — | — | EP | disclosed |
| EP-4619386-A1 | ARYL THIOETHERS AS HIF-2ALPHA INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-09-24 | — | — | EP | disclosed |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025049419-A1 | PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS | GENZYME CORPORATION (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025040546-A1 | PYRAZOLE COMPOUNDS AS CULLIN RING UBIQUITIN LIGASE COMPOUNDS | PROXYGEN GMBH (AT) | 2025-02-27 | — | — | WO | disclosed |
| WO-2025014200-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 티움바이오 | 2025-01-16 | — | — | WO | disclosed |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-20090012304-A1 | preparation of intermediates 3-[3-(4-methyl-5-methylsulfanyl-4H-[1,2,4]triazol-3-ylmethyl)phenoxy]-5-difluoromethyl-benzonitrile derivatives; for making enzyme inhibitors of HIV-1 reverse transcriptase, treating AIDS and HIV-1 syndromes | ROCHE PALO ALTO LLC | 2009-01-08 | — | — | US | disclosed |
| CN-1312151-C | (imidazol-1-yl-methyl)-pyridazine as NMDA receptor blocker | HOFFMANN LA ROCHE (CH) | 2007-04-25 | — | — | CN | disclosed |
| EP-1506190-B1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | HOFFMANN LA ROCHE (CH) | 2006-06-14 | — | — | EP | disclosed |
| US-7005432-B2 | Substituted imidazol-pyridazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | disclosed |
| CN-1653062-A | (imidazol-1-yl-methyl)-pyridazine as NMDA receptor blocker | HOFFMANN LA ROCHE (CH) | 2005-08-10 | — | — | CN | disclosed |
| EP-1506190-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| WO-2003097637-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | CHRNB4 3315/4885CHRNA3 3233/4885IDO1 4276/4885 |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | GRIN2B, GRIN2A, GRIN2C | CHRNB4 47/4885CHRNA3 57/4885IDO1 1496/4885 |
| US-12552826-B2 | PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | CHRNB4 2004/4885CHRNA3 1655/4885IDO1 3073/4885 |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | CHRNB4 3315/4885CHRNA3 3233/4885IDO1 4276/4885 |
| US-20090012304-A1 | preparation of intermediates 3-[3-(4-methyl-5-methylsulfanyl-4H-[1,2,4]triazol-3-ylmethyl)phenoxy]-5-difluoromethyl-benzonitrile derivatives; for making enzyme inhibitors of HIV-1 reverse transcriptase, treating AIDS and HIV-1 syndromes | POLRMT, TYMS, POLR1G | CHRNB4 4186/4885CHRNA3 4475/4885IDO1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.